CN113133531A - Compound protein supplement and preparation method thereof - Google Patents
Compound protein supplement and preparation method thereof Download PDFInfo
- Publication number
- CN113133531A CN113133531A CN202010062542.7A CN202010062542A CN113133531A CN 113133531 A CN113133531 A CN 113133531A CN 202010062542 A CN202010062542 A CN 202010062542A CN 113133531 A CN113133531 A CN 113133531A
- Authority
- CN
- China
- Prior art keywords
- protein
- oligosaccharide
- supplement
- composite
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940116540 protein supplement Drugs 0.000 title claims abstract description 18
- 235000005974 protein supplement Nutrition 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 title description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 24
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 23
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 11
- 150000003271 galactooligosaccharides Chemical group 0.000 claims abstract description 11
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 9
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 8
- 235000018102 proteins Nutrition 0.000 claims description 51
- 239000000843 powder Substances 0.000 claims description 14
- 108010046377 Whey Proteins Proteins 0.000 claims description 13
- 102000007544 Whey Proteins Human genes 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 13
- 235000021119 whey protein Nutrition 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 11
- 108010076119 Caseins Proteins 0.000 claims description 7
- 108010028690 Fish Proteins Proteins 0.000 claims description 6
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 239000013589 supplement Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 abstract description 19
- 238000002512 chemotherapy Methods 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 230000003115 biocidal effect Effects 0.000 abstract description 4
- 239000006041 probiotic Substances 0.000 abstract description 3
- 235000018291 probiotics Nutrition 0.000 abstract description 3
- 208000002720 Malnutrition Diseases 0.000 abstract description 2
- 230000001071 malnutrition Effects 0.000 abstract description 2
- 235000000824 malnutrition Nutrition 0.000 abstract description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract description 2
- 235000019621 digestibility Nutrition 0.000 abstract 2
- 239000000047 product Substances 0.000 description 30
- 241000700159 Rattus Species 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 102000011632 Caseins Human genes 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- FBJQEBRMDXPWNX-FYHZSNTMSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-FYHZSNTMSA-N 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 235000021075 protein intake Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003623 Hypoalbuminemia Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000003691 alpha-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000001076 sarcopenia Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- ZCLAHGAZPPEVDX-UHFFFAOYSA-N D-panose Natural products OC1C(O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC1COC1C(O)C(O)C(O)C(CO)O1 ZCLAHGAZPPEVDX-UHFFFAOYSA-N 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 239000004267 EU approved acidity regulator Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- ZCLAHGAZPPEVDX-MQHGYYCBSA-N panose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCLAHGAZPPEVDX-MQHGYYCBSA-N 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound protein supplement suitable for tumor patients, perioperative patients, burn patients and elderly people with malnutrition. The method is characterized in that: it is composed of high-quality protein and oligosaccharide composition. The high-quality protein has the characteristics of high biological value, high digestibility, high protein and high utilization rate, and is matched with the oligosaccharide composition of galacto-oligosaccharide, fructo-oligosaccharide and isomalto-oligosaccharide which can effectively proliferate the intestinal probiotics, so that the protein can be quickly supplemented for a human body, the intestinal probiotics of the human body can be effectively proliferated, the balance of intestinal flora of the human body can be adjusted, the problem of intestinal flora imbalance of a patient caused by chemotherapy or antibiotic treatment is avoided, and the digestibility of the protein is further improved.
Description
Technical Field
The invention belongs to the technical field of medical food, and particularly relates to a composite protein supplement and a preparation method thereof.
Background
Multiple factors lead to high nutritional risk and increased protein consumption in patients during perioperative periods. Surgery and trauma cause stress in the body, which leads to metabolic changes. Increased basal metabolic rate, enhanced insulin resistance, negative nitrogen balance and acute phase response protein synthesis; under stress conditions such as surgery, trauma, infection, etc., the body breaks down more proteins and essential amino acids, and the body's demand for proteins far exceeds the increased energy expenditure.
Promoting wound healing, body injuries and surgical wound healing requires a high enough quality protein, an essential substance for epithelial growth repair. Inadequate or poor quality protein intake can prolong or even prevent healing of the injury.
The general rules for tumor nutrition treatment include: the protein target of the tumor patients needs 1.2-1.5g/(kg d), and the protein target of the dyscrasia patients needs 1.8-2 g/(kg d). Increasing protein intake can enhance muscle protein anabolism in a patient.
A large amount of plasma protein of a burn patient seeps out of a blood vessel and is accumulated in a tissue gap or seeps out of the body, so hypoalbuminemia is caused, particularly, a large amount of albumin is lost, hypoalbuminemia is caused, muscle tissue and subcutaneous fat tissue are consumed, and endogenous fat and protein reserves are empty, so that a plurality of organs are damaged, and the patient is easy to suffer from infection or other complications.
The digestive ability of the old is reduced, the nutrient substance intake of the body is insufficient, and the muscle tissue of the body is reduced. Sarcopenia is a common disease symptom which is caused by aging and is characterized by obvious reduction of muscle quality and muscle strength, and is accompanied by functional decline and various chronic diseases. The intake of sufficient dietary protein and energy, as well as the enhancement of resistance exercise and aerobic exercise are important measures for the prevention and treatment of sarcopenia in the elderly.
In addition, perioperative period, burn and tumor people can receive a large amount of antibiotics and radiotherapy and chemotherapy treatment, and the beneficial bacteria in intestinal tracts are reduced and harmful bacteria are proliferated, so that symptoms such as diarrhea, constipation, dyspepsia and the like are caused; the elderly are also prone to intractable constipation due to gastrointestinal tract function deterioration. In these cases, even large doses of protein supplements do not provide the desired effect due to intestinal dysfunction. Therefore, it is necessary to improve the imbalance of the intestinal flora while supplementing the protein, so that the bioavailability of the protein can be improved, and the function of the protein can be maximized.
Under the condition of normal diet, the people above cannot meet the requirements of the body on protein, particularly the requirements on high-quality protein, and need to supplement high-quality protein additionally and efficiently. The protein sources of the current commercial protein products are soybean protein, casein, livestock and poultry meat, peanut protein and the like, the selected protein raw materials have different nutritional values, and the Amino Acid Scores (AAS) also have great differences, namely, the degrees of digestion, absorption and utilization of different protein raw materials by human bodies are also different. Analyzing the existing protein products in the market, more or less the following problems exist: 1. the protein raw material has wide source, and the nutritive value in unit dose is high or low; 2. the protein content is moderate and low; 3. the main components of the product do not contain an intestinal flora imbalance regulator, so that the digestion and absorption of protein are slow, and the bioavailability is low; therefore, it is not very suitable for the above-mentioned special population. Therefore, it is necessary to comprehensively study and solve the above problems.
Disclosure of Invention
The invention aims to provide a compound protein supplement for perioperative period, burn, tumor and elderly people with malnutrition and a preparation method thereof, and the compound protein supplement can quickly provide high-quality protein supplement for patients and simultaneously improve the problem of intestinal flora imbalance of the patients caused by chemotherapy or antibiotic treatment.
In order to achieve the above technical problem, the technical solution of the present invention includes: a supplement having a high quality protein and oligosaccharide composition, and a method of making the same.
The supplement is characterized in that the protein content is more than or equal to 75 percent; preferably, the protein content is more than or equal to 80%; more preferably, the protein content is > 85%.
The protein is high-quality protein, and the high-quality protein comprises the following sources: one or more of whey protein, casein, fish protein and hydrolysate thereof; preferably whey protein, fish protein; more preferably isolated whey protein.
The oligosaccharide composition is an oligosaccharide composition containing galacto-oligosaccharide, fructo-oligosaccharide and isomalto-oligosaccharide, and the weight ratio is as follows: 1:1: 1-10: 1: 1; preferably: 5:1: 1-10: 1: 1; more preferably 8:1:1 to 10:1: 1.
The form of the composite protein supplement comprises: protein powder or granule, protein candy. Preferably a protein powder or a granulate.
The composite protein supplement is characterized by comprising food additives allowed to be added into food.
The casein is defined as follows: having its ordinary meaning in the art. Is a natural milk source. Belongs to high-quality protein. The casein in the text is casein powder and hydrolysate thereof or sodium caseinate.
The fish protein is as follows: having its ordinary meaning in the art. Is derived from fish meat or fish skin. Belongs to high-quality protein. Fish protein herein includes fish meat and fish collagen and hydrolysates thereof. The amino acid composition proportion is balanced, the essential amino acid content is high, and the digestion and absorption rate is high.
The "whey protein" referred to in the present specification is: having its ordinary meaning in the art. Is a natural milk source. Belongs to high-quality protein. The whey protein in the invention is whey protein powder and hydrolysate thereof, the protein content is more than or equal to 75% (w/w), preferably concentrated whey protein powder, the protein content is more than or equal to 80% (w/w), more preferably isolated whey protein powder, and the protein content is more than or equal to 90% (w/w).
The main physiological functions of the oligosaccharide composition are mainly shown in the aspects of improving the intestinal function, enhancing the immunity of the organism and the like, and the functions are mainly realized by optimizing and balancing the intestinal flora of a human body and promoting the proliferation of beneficial bacteria in the intestinal tract, so that the oligosaccharide composition can help people to maintain the intestinal microecological balance, relieve constipation, regulate blood fat, promote mineral absorption, improve the immunity and the like. The oligosaccharide is added into the protein powder, so that the protein powder has a specific function, new requirements of patients and old patients on nutrition and health are met, and the intestinal flora balance of the patients is favorably established to quickly recover health.
The functional oligosaccharide comprises fructo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide, xylo-oligosaccharide, soybean oligosaccharide, mannose oligomer, stachyose, raffinose, etc. The oligosaccharide composition is an oligosaccharide composition containing galacto-oligosaccharide, fructo-oligosaccharide and isomalto-oligosaccharide. Wherein:
the "galactooligosaccharides" in the present description are: the term "galactooligosaccharide" as used herein also includes mixtures of galactooligosaccharides as the main component. Preferably, the mixture of galactooligosaccharides as the main component has a galactooligosaccharide content of not less than 50% (w/w), more preferably 95% (w/w).
The fructooligosaccharides referred to in the present description are: having its ordinary meaning in the art. The fructo-oligosaccharide is functional oligosaccharide with fructosyl connected by beta-glycosidic bond, alpha-D-glucosyl at the end and polymerization degree of 3-9 or no alpha-D-glucosyl and polymerization degree of 2-9. The raw material source can be sucrose, or plant such as Jerusalem artichoke, herba Cichorii, etc. The form is solid powder. The content of the fructo-oligosaccharide is more than or equal to 50 percent (w/w). Preferably, the content of the fructo-oligosaccharide is more than or equal to 70.0 percent (w/w). More preferably, the content of fructo-oligosaccharide is 95.0% (w/w) or more.
The "isomaltooligosaccharides" in the present description are: having its ordinary meaning in the art. Isomaltooligosaccharides herein are starch sugars, and alpha-1, 6-glycosidically bound Isomaltose (IG) is the main component2) Panose (P), Isomaltotriose (IG)3) And tetrasaccharide (containing tetrasaccharide) or more (G)n) The oligosaccharide of (4). The content of isomaltooligosaccharide is more than or equal to 50% (w/w), preferably, the content of isomaltooligosaccharide is more than or equal to 90% (w/w).
The ingredients and additives included in the composition of the present invention are in the field of food products, such as acidity regulators, flavors, sweeteners, etc.
Advantageous effects
The protein content of the product is far higher than that of the products, the product is 1-3 times of that of the similar products, the main component protein is whey protein, the whey protein belongs to high-quality protein, the digestion is easier, the absorption rate is high, no extra carbohydrate and fat are added to people who need to supplement protein urgently, the effectiveness is improved, and the cost performance is higher.
Aiming at the intestinal flora imbalance phenomenon of the specific population, such as gastrointestinal dyspepsia, nausea, vomiting, constipation, diarrhea and the like, the appetite and the self-digestion and absorption functions of the patients are seriously influenced. With the combination of specific oligosaccharide compositions, a significant synergistic effect is produced: the feed additive has the advantages of regulating the intestinal flora of a human body, obviously proliferating probiotics, regulating the microenvironment balance of the intestinal flora, improving the intestinal environment and enabling protein to be absorbed more easily.
Detailed Description
The present invention will be further described with reference to the following examples, but the present invention is not limited thereto. Equivalent substitutions or modifications of the present disclosure by those skilled in the art are also within the scope of the present disclosure.
Product example 1:
product example 2:
product example 3:
product example 4:
product example 5:
in the case of a powdered product, the entire process is operated in a clean zone in order to ensure the quality of the product. The preparation method comprises the steps of screening the raw materials through a 60-100-mesh sieve, weighing the raw materials and the auxiliary materials according to the formula, mixing the oligosaccharide composition and the sweetening agent for 8-15min to obtain a mixed material, adding part of the protein raw material, mixing for 10-20min to obtain a semi-mixed material 1, adding the rest of the protein raw material, mixing for 10-20min to obtain a semi-mixed material 2, mixing essence with the semi-mixed material 2, and mixing for 10-30min to obtain a final powder product, preferably packaging with aluminum plastic.
In the case of granular products, the entire process is operated in a clean zone in order to guarantee the quality of the product. The preparation method comprises the steps of screening the raw materials through a 60-100-mesh sieve, weighing the raw materials and the auxiliary materials according to the formula, mixing the oligosaccharide composition and the sweetening agent for 8-15min to obtain a mixed material, adding part of the protein raw material, mixing for 10-20min to obtain a semi-mixed material 1, adding the rest of the protein raw material, mixing for 10-20min to obtain a semi-mixed material 2, mixing essence with the semi-mixed material 2, granulating with 85% ethanol, drying, packaging, and preferably packaging with aluminum plastic.
The compositions of the invention may be in a form suitable for enteral administration, preferably both oral administration and administration via a tube or catheter are encompassed by the invention. The compositions of the present invention may be used or self-administered under the direction of a physician or clinical dietician.
Test example 1: the product of the invention is used for carrying out a human body feeding trial experiment, and 108 malignant tumor patients treated in a hospital are randomly selected as study objects. All patients were diagnosed cytologically or pathologically and were proposed for chemotherapy. All patients were randomly divided into normal diet group, control group and product group of the invention, and three groups of patients had no significant difference (P > 0.05) in sex, age and disease category and were comparable. Exclusion criteria: 1. serious dysfunction of vital organs such as liver and kidney; 2. unclear consciousness and unable to communicate normally; 3. quitting in the middle of the test; 4. prolonged hospitalization due to non-chemotherapy; 5. chemotherapy regimens have high emetic drugs; the statistical indexes of two groups of patients are shown in table 5, and the indexes have no statistical difference and are comparable.
TABLE 6 nutritional status index for each group of patients before the experiment
The treatment regimens for three groups of patients were: the normal diet group was subjected to a regular diet regimen; when the control group is subjected to diet nursing, besides ensuring a conventional scheme, the control group is supplemented with certain brand commercial protein powder (with 75 percent of protein content and 2 percent of inulin) of the same type according to the requirements of different patients; the group of products according to the invention was supplemented according to the needs of different patients, in addition to ensuring a regular regimen when taking dietary care. The administration is continued for 30 days. Quality of life assessment using the core quality of life scale established for european disease research and treatment (EORTC QLQ-C30): 6 areas of symptoms (nausea vomiting, loss of appetite, constipation, diarrhea, pain, economic difficulties). The entry scores were 4 grades: none, a few 2, some 3, and very much 4 points. The higher the symptom scale score, the more severe the symptoms.
TABLE 7 comparison of relevant indices for groups of patients after the test
Note: p <0.05, P <0.01, compared to control group
Table 7 shows that after the test period, the total protein, albumin and hemoglobin indexes of the product group are significantly increased (P < 0.05) compared with the control group, the incidence rate of adverse reactions (appetite loss, constipation and diarrhea) of the product group is obviously lower than that of the control group (P < 0.05), and the economic difficulty condition is obviously better than that of the control group (P < 0.05).
Chemotherapy is a very common method for treating malignant tumors, and the plasma protein level is obviously reduced after multiple times of chemotherapy, so that the drugs in the body of a patient are subjected to metabolic disorder, and the treatment effect of the drugs is poor indirectly. In conclusion, the composition of the protein and the oligosaccharide has obvious nutrition supporting effect on patients with tumor chemotherapy, and has important effects on improving the immunity of the patients and indirectly reducing the incidence rate of adverse reactions. The composition of protein and oligosaccharide can regulate the function of intestinal flora while supplementing protein, and has very positive effect on the application of products.
Test example 2: SD rats were randomly divided into 3 groups: blank, control and product of the invention groups, 15 per group. The three groups of rats freely drink antibiotic solution (clindamycin hydrochloride is dissolved in 25% sucrose aqueous solution, the mass concentration is 0.30 mg/mL), fresh excrement of the rats is collected every day, excrement bacteria are cultured, the change of the total anaerobic bacteria and the quantity of bifidobacteria is observed, the quantity of viable bacteria is reduced by more than 100 times, and the establishment of an antibiotic intestinal flora imbalance model is successful. The intestinal flora imbalance model is established, three groups of rats on the same day are used for preparing a wound model, and the preparation method of the wound model comprises the following steps: 2 wound surfaces with the diameter of about 2.5 centimeters are made on the same parts of the spinal column on the hip-proximal side of the back of a rat by a surgical method, and a blank group of free diet drinking water is obtained after a wound model is established; continuously gavage a certain brand of commercial protein powder (protein content 75% and prebiotics content 2%) to rats of a control group according to 0.5 g/kg/d; the product group rats are continuously gavaged with the product of the invention according to 0.5g/kg/d, and the test object is continuously gavaged for 10 days after the wound model is established.
After the end of the test period, the test animals were treated as follows: (1) fresh feces of rats were aseptically collected, and the number of total anaerobic bacteria and bifidobacteria in the feces was counted for viable bacteria. (2) Injecting 10% chloral hydrate (0.03 ml/kg) into the abdominal cavity, drawing a wound surface graph by using a transparent film after anesthesia is successful for calculating the wound surface healing rate, wherein the wound surface healing rate = [ (area before nutrition implementation-area after nutrition implementation)/area before nutrition implementation ]. 100%. Blood is taken by an in-vitro heart blood sampling method, serum is prepared, and the total protein, albumin and hemoglobin content of the serum is measured by a conventional automatic biochemical analyzer method.
TABLE 8 Biochemical index of serum and the change of fecal flora after the experiment
As can be seen in table 8, after the test period is over, the indexes of total serum protein, albumin and hemoglobin of the rats in the product group of the invention are significantly increased (P < 0.05) compared with the indexes of the control group; the wound healing rate of the product group is obviously higher than that of a control group (P is less than 0.05); the results show that the total anaerobic bacteria and the bifidobacteria of the product group are also obviously increased (P <0.05 and P < 0.01) through the fecal viable bacteria counting, and the results show that the product has good promotion effect on the wound healing of rats and can obviously improve the imbalance phenomenon of antibiotic intestinal flora.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (9)
1. A composite protein supplement is characterized by mainly comprising a high-quality protein and oligosaccharide composition.
2. The composite protein supplement of claim 1, wherein the high quality protein content is greater than or equal to 75%; preferably, the content of the high-quality protein is more than or equal to 80 percent; more preferably, the high quality protein content is greater than or equal to 85%.
3. The composite protein supplement of claim 1 or 2, wherein the high quality protein is one or more of whey protein, casein, fish protein and hydrolysates thereof.
4. The composite protein supplement of claim 3, wherein the high quality protein is preferably whey protein, fish protein; more preferably isolated whey protein.
5. The composite protein supplement according to claim 1 or 2, wherein the oligosaccharide composition is a composition of galacto-oligosaccharides, fructo-oligosaccharides and isomalto-oligosaccharides.
6. The oligosaccharide composition of claim 5, wherein the weight ratio of galacto-oligosaccharide, fructo-oligosaccharide to isomalto-oligosaccharide in the oligosaccharide composition is: 1:1: 1-10: 1: 1; preferably: 5:1: 1-10: 1: 1; more preferably 8:1:1 to 10:1: 1.
7. The composite protein supplement of claim 1, wherein a desired food additive may be added.
8. The composite protein supplement of claim 1, wherein the supplement dosage form is a conventional dosage form such as powder or granule; powders and granules are preferred.
9. The method of preparing a composite protein supplement of claim 1, wherein the raw materials are sieved through a 60-100 mesh sieve, mixed in an equal incremental process to ensure a powdered finish in its state and homogeneity, and granulated with ethanol, oven dried and pulverized.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010062542.7A CN113133531A (en) | 2020-01-20 | 2020-01-20 | Compound protein supplement and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010062542.7A CN113133531A (en) | 2020-01-20 | 2020-01-20 | Compound protein supplement and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113133531A true CN113133531A (en) | 2021-07-20 |
Family
ID=76808744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010062542.7A Pending CN113133531A (en) | 2020-01-20 | 2020-01-20 | Compound protein supplement and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113133531A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115918914A (en) * | 2022-12-01 | 2023-04-07 | 宝健（北京）生物技术有限公司 | Oral nutritional supplement containing compound protein, preparation and application |
| CN116687003A (en) * | 2022-02-24 | 2023-09-05 | 亚宝药业集团股份有限公司 | Nutritional composition for old-aged gastrointestinal tumor resection patients |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101449815A (en) * | 2007-11-30 | 2009-06-10 | 天津市鸿禄食品有限公司 | Infant composite protein nutrient powder |
| CN102960603A (en) * | 2012-12-12 | 2013-03-13 | 山东龙力生物科技股份有限公司 | Nutrient protein powder with high digestive absorption function |
| CN109673814A (en) * | 2019-02-19 | 2019-04-26 | 刘良忠 | A kind of preparation method of the compound protein powder of homoamino acid scoring |
-
2020
- 2020-01-20 CN CN202010062542.7A patent/CN113133531A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101449815A (en) * | 2007-11-30 | 2009-06-10 | 天津市鸿禄食品有限公司 | Infant composite protein nutrient powder |
| CN102960603A (en) * | 2012-12-12 | 2013-03-13 | 山东龙力生物科技股份有限公司 | Nutrient protein powder with high digestive absorption function |
| CN109673814A (en) * | 2019-02-19 | 2019-04-26 | 刘良忠 | A kind of preparation method of the compound protein powder of homoamino acid scoring |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116687003A (en) * | 2022-02-24 | 2023-09-05 | 亚宝药业集团股份有限公司 | Nutritional composition for old-aged gastrointestinal tumor resection patients |
| CN115918914A (en) * | 2022-12-01 | 2023-04-07 | 宝健（北京）生物技术有限公司 | Oral nutritional supplement containing compound protein, preparation and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6929793B2 (en) | Nutritional composition for treating an immune condition | |
| CN111616232A (en) | Children milk powder for promoting bone growth and preparation method thereof | |
| CN113491289A (en) | Breast milk oligosaccharide capable of improving resistance of organism to staphylococcus aureus infection | |
| CN105795468A (en) | Composition having efficacy of losing weight | |
| CN111972672A (en) | Composition with muscle increasing function and application thereof | |
| EP0546870A1 (en) | Nutritive composition for prevention and therapy of infection diseases caused by immunosuppression | |
| CN105011151A (en) | Composite prebiotics capable of regulating intestinal tract function of human body | |
| WO2002052954A2 (en) | Nutritional composition for a bone condition | |
| CN113133531A (en) | Compound protein supplement and preparation method thereof | |
| JPH03151854A (en) | Composition for improving intestinal environment | |
| TW200810762A (en) | Use of DNA and ARA in the preparation of a composition for the prevention or treatment of anemia | |
| CN111543605A (en) | Comprehensive nutrition powder for people with hypertension, hyperlipidemia and obesity | |
| CN110710660A (en) | Blood sugar lowering composition and dietary supplement containing bitter gourd powder | |
| Anderson et al. | Nutritional therapy for adults with renal disease | |
| CN104642732A (en) | Meat duck feed additive and use thereof | |
| CN111406935A (en) | Carbohydrate component formula food suitable for preoperative taking and having special medical application and application thereof | |
| Dahlstrom et al. | Nutritional status in children receiving home parenteral nutrition | |
| WO2024082677A1 (en) | Hypoallergenic milk having immunity improving function and preparation method therefor | |
| CN110638842A (en) | Probiotics composition for improving hyperglycemia | |
| EP4346450A1 (en) | Infant formula for feeding infants receiving infant formula and human breast milk | |
| CN115702654A (en) | Middle-aged and old-aged modified goat milk powder assisting in reducing blood sugar and preparation method thereof | |
| CN1545937A (en) | Children health food containing prebiotics and preparation method thereof | |
| WO2021189249A1 (en) | Maternal formula milk powder promoting maternal and infant health | |
| CN112715961A (en) | Food composition for promoting muscle growth of elderly diabetic patients | |
| Nikolaev et al. | Innovative technology of pork production with the use of phytobiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210720 |